{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:47:37Z","timestamp":1790711257511,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Disease modifying therapies aiming to preserve \u03b2-cell function in patients with adult-onset autoimmune type 1 diabetes are lacking. Here, we conducted a multi-centre, randomized, controlled trial to assess the \u03b2-cell preservation effects of saxagliptin alone and saxagliptin combined with vitamin D as adjunctive therapies in adult-onset autoimmune type 1 diabetes. In this 3-arm trial, 301 participants were randomly assigned to a 24-month course of the conventional therapy (metformin with or without insulin) or adjunctive saxagliptin or adjunctive saxagliptin plus vitamin D to the conventional therapy. The primary endpoint was the change from baseline to 24\u2009months in the fasting C-peptide. The secondary endpoints included the area under the concentration-time curve (AUC) for C-peptide level in a 2-h mixed-meal tolerance test, glycemic control, total daily insulin use and safety, respectively. The primary endpoint was not achieved in saxagliptin plus vitamin D group (<jats:italic>P<\/jats:italic>\u2009=\u20090.18) and saxagliptin group (<jats:italic>P<\/jats:italic>\u2009=\u20090.26). However, compared with the conventional therapy, 2-h C-peptide AUC from 24\u2009months to baseline decreased less with saxagliptin plus vitamin D (-276 pmol\/L vs. -419 pmol\/L; <jats:italic>P<\/jats:italic>\u2009=\u20090.01), and not to the same degree with saxagliptin alone (-314 pmol\/L; <jats:italic>P<\/jats:italic>\u2009=\u20090.14). Notably, for participants with higher glutamic acid decarboxylase antibody (GADA) levels, the decline of \u03b2-cell function was much lower in saxagliptin plus vitamin D group than in the conventional therapy group (<jats:italic>P<\/jats:italic>\u2009=\u20090.001). Insulin dose was significantly reduced in both active treatment groups than in the conventional therapy group despite all groups having similar glycemic control. In conclusion, the combination of saxagliptin and vitamin D preserves pancreatic \u03b2-cell function in adult-onset autoimmune type 1 diabetes, an effect especially efficacious in individuals with higher GADA levels. Our results provide evidence for a novel adjunct to insulin and metformin as potential initial treatment for adult-onset type 1 diabetes. (ClinicalTrials.gov identifier: NCT02407899).<\/jats:p>","DOI":"10.1038\/s41392-023-01369-9","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:02:28Z","timestamp":1681948948000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Combination therapy with saxagliptin and vitamin D for the preservation of \u03b2-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial"],"prefix":"10.1038","volume":"8","author":[{"given":"Xiang","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houde","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangbing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1786-1531","authenticated-orcid":false,"given":"Richard David","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"1369_CR1","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1126\/science.abh1654","volume":"373","author":"JA Bluestone","year":"2021","unstructured":"Bluestone, J. A. et al. Immunotherapy: Building a bridge to a cure for type 1 diabetes. Science 373, 510\u2013516 (2021).","journal-title":"Science"},{"key":"1369_CR2","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.2337\/dc21-0770","volume":"44","author":"RD Leslie","year":"2021","unstructured":"Leslie, R. D. et al. Adult-onset type 1 diabetes: current understanding and challenges. Diabetes Care 44, 2449\u20132456 (2021).","journal-title":"Diabetes Care"},{"key":"1369_CR3","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.2337\/dci21-0043","volume":"44","author":"RIG Holt","year":"2021","unstructured":"Holt, R. I. G. et al. The management of type 1 diabetes in adults. A consensus report by the american diabetes association (ada) and the european association for the study of diabetes (easd). Diabetes Care. 44, 2589\u20132625 (2021).","journal-title":"Diabetes Care."},{"key":"1369_CR4","doi-asserted-by":"publisher","first-page":"107842","DOI":"10.1016\/j.diabres.2019.107842","volume":"157","author":"CC Patterson","year":"2019","unstructured":"Patterson, C. C. et al. Worldwide estimates of incidence, prevalence and mortality of type 1 diabetes in children and adolescents: Results from the international diabetes federation diabetes atlas, 9th edition. Diabetes Res Clin. Pr. 157, 107842 (2019).","journal-title":"Diabetes Res Clin. Pr."},{"key":"1369_CR5","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.tem.2018.07.001","volume":"29","author":"R Mishra","year":"2018","unstructured":"Mishra, R. et al. A global perspective of latent autoimmune diabetes in adults. Trends Endocrinol. Metab. 29, 638\u2013650 (2018).","journal-title":"Trends Endocrinol. Metab."},{"key":"1369_CR6","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00592-015-0799-8","volume":"52","author":"Y Xiang","year":"2015","unstructured":"Xiang, Y. et al. Glutamic acid decarboxylase autoantibodies are dominant but insufficient to identify most chinese with adult-onset non-insulin requiring autoimmune diabetes: Lada china study 5. Acta Diabetol. 52, 1121\u20131127 (2015).","journal-title":"Acta Diabetol."},{"key":"1369_CR7","doi-asserted-by":"publisher","first-page":"994","DOI":"10.2337\/dc21-1752","volume":"45","author":"JL Harding","year":"2022","unstructured":"Harding, J. L. et al. The incidence of adult-onset type 1 diabetes: a systematic review from 32 countries and regions. Diabetes Care 45, 994\u20131006 (2022).","journal-title":"Diabetes Care"},{"key":"1369_CR8","doi-asserted-by":"crossref","unstructured":"Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The diabetes control and complications trial research group. Ann. Intern Med. 128, 517\u2013523 (1998).","DOI":"10.7326\/0003-4819-128-7-199804010-00001"},{"key":"1369_CR9","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.2337\/dbi20-0017","volume":"69","author":"R Buzzetti","year":"2020","unstructured":"Buzzetti, R. et al. Management of latent autoimmune diabetes in adults: a consensus statement from an international expert panel. Diabetes 69, 2037\u20132047 (2020).","journal-title":"Diabetes"},{"key":"1369_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S2213-8587(21)00019-X","volume":"9","author":"M von Herrath","year":"2021","unstructured":"von Herrath, M. et al. Anti-interleukin-21 antibody and liraglutide for the preservation of beta-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 9, 212\u2013224 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1369_CR11","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1210\/jc.2013-3633","volume":"99","author":"Y Zhao","year":"2014","unstructured":"Zhao, Y. et al. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains beta-cell function in patients with recent-onset latent autoimmune diabetes in adults: One year prospective study. J. Clin. Endocrinol. Metab. 99, e876\u2013e880 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1369_CR12","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.2337\/db09-1618","volume":"59","author":"SJ Kim","year":"2010","unstructured":"Kim, S. J. et al. Sitagliptin (mk0431) inhibition of dipeptidyl peptidase iv decreases nonobese diabetic mouse cd4+ t-cell migration through incretin-dependent and -independent pathways. Diabetes 59, 1739\u20131750 (2010).","journal-title":"Diabetes"},{"key":"1369_CR13","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2337\/db08-1101","volume":"58","author":"SJ Kim","year":"2009","unstructured":"Kim, S. J. et al. Dipeptidyl peptidase iv inhibition with mk0431 improves islet graft survival in diabetic nod mice partially via t-cell modulation. Diabetes 58, 641\u2013651 (2009).","journal-title":"Diabetes"},{"key":"1369_CR14","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1182\/blood-2005-05-2044","volume":"106","author":"G Penna","year":"2005","unstructured":"Penna, G. et al. Expression of the inhibitory receptor ilt3 on dendritic cells is dispensable for induction of cd4+foxp3+ regulatory t cells by 1,25-dihydroxyvitamin d3. Blood 106, 3490\u20133497 (2005).","journal-title":"Blood"},{"key":"1369_CR15","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.cell.2018.04.013","volume":"173","author":"Z Wei","year":"2018","unstructured":"Wei, Z. et al. Vitamin d switches baf complexes to protect beta cells. Cell 173, 1135\u20131149 e1115 (2018).","journal-title":"Cell"},{"key":"1369_CR16","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1016\/S0140-6736(16)30507-4","volume":"387","author":"M Rewers","year":"2016","unstructured":"Rewers, M. et al. Environmental risk factors for type 1 diabetes. Lancet 387, 2340\u20132348 (2016).","journal-title":"Lancet"},{"key":"1369_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/dmrr.977","volume":"25","author":"X Li","year":"2009","unstructured":"Li, X. et al. Protective effects of 1-alpha-hydroxyvitamin d3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (lada). Diabetes Metab. Res Rev. 25, 411\u2013416 (2009).","journal-title":"Diabetes Metab. Res Rev."},{"key":"1369_CR18","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.2337\/db13-1559","volume":"63","author":"T Takiishi","year":"2014","unstructured":"Takiishi, T. et al. Dietary supplementation with high doses of regular vitamin d3 safely reduces diabetes incidence in nod mice when given early and long term. Diabetes 63, 2026\u20132036 (2014).","journal-title":"Diabetes"},{"key":"1369_CR19","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s41588-021-00948-2","volume":"53","author":"D Mansour Aly","year":"2021","unstructured":"Mansour Aly, D. et al. Genome-wide association analyses highlight etiological differences underlying newly defined subtypes of diabetes. Nat. Genet 53, 1534\u20131542 (2021).","journal-title":"Nat. Genet"},{"key":"1369_CR20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","volume":"6","author":"E Ahlqvist","year":"2018","unstructured":"Ahlqvist, E. et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 6, 361\u2013369 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1369_CR21","doi-asserted-by":"publisher","first-page":"e3298","DOI":"10.1002\/dmrr.3298","volume":"36","author":"Z Zhang","year":"2020","unstructured":"Zhang, Z. et al. Adding vitamin d3 to the dipeptidyl peptidase-4 inhibitor saxagliptin has the potential to protect beta-cell function in lada patients: a 1-year pilot study. Diabetes Metab. Res Rev. 36, e3298 (2020).","journal-title":"Diabetes Metab. Res Rev."},{"key":"1369_CR22","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.2337\/diabetes.52.5.1059","volume":"52","author":"CJ Greenbaum","year":"2003","unstructured":"Greenbaum, C. J. et al. Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes 52, 1059\u20131065 (2003).","journal-title":"Diabetes"},{"key":"1369_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s00125-018-4768-y","volume":"62","author":"F Pociot","year":"2019","unstructured":"Pociot, F. Capturing residual beta cell function in type 1 diabetes. Diabetologia 62, 28\u201332 (2019).","journal-title":"Diabetologia"},{"key":"1369_CR24","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s00125-010-1988-1","volume":"54","author":"J Ludvigsson","year":"2011","unstructured":"Ludvigsson, J. et al. Extended evaluation of the safety and efficacy of gad treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial. Diabetologia 54, 634\u2013640 (2011).","journal-title":"Diabetologia"},{"key":"1369_CR25","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa0804328","volume":"359","author":"J Ludvigsson","year":"2008","unstructured":"Ludvigsson, J. et al. Gad treatment and insulin secretion in recent-onset type 1 diabetes. N. Engl. J. Med 359, 1909\u20131920 (2008).","journal-title":"N. Engl. J. Med"},{"key":"1369_CR26","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.2337\/dc13-1523","volume":"37","author":"OE Johansen","year":"2014","unstructured":"Johansen, O. E. et al. C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: Exploratory results from a 2-year double-blind, randomized, controlled study. Diabetes Care 37, e11\u2013e12 (2014).","journal-title":"Diabetes Care"},{"key":"1369_CR27","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1111\/dom.13797","volume":"21","author":"IK Hals","year":"2019","unstructured":"Hals, I. K. et al. Investigating optimal beta-cell-preserving treatment in latent autoimmune diabetes in adults: Results from a 21-month randomized trial. Diabetes Obes. Metab. 21, 2219\u20132227 (2019).","journal-title":"Diabetes Obes. Metab."},{"key":"1369_CR28","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/dmrr.2717","volume":"32","author":"R Buzzetti","year":"2016","unstructured":"Buzzetti, R. et al. Saxagliptin improves glycaemic control and c-peptide secretion in latent autoimmune diabetes in adults (lada). Diabetes Metab. Res Rev. 32, 289\u2013296 (2016).","journal-title":"Diabetes Metab. Res Rev."},{"key":"1369_CR29","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/S2213-8587(14)70115-9","volume":"2","author":"KJ Griffin","year":"2014","unstructured":"Griffin, K. J. et al. Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (repair-t1d): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2, 710\u2013718 (2014).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1369_CR30","doi-asserted-by":"publisher","first-page":"e2192","DOI":"10.1210\/clinem\/dgaa149","volume":"105","author":"P Pozzilli","year":"2020","unstructured":"Pozzilli, P. et al. Randomized 52-week phase 2 trial of albiglutide versus placebo in adult patients with newly diagnosed type 1 diabetes. J. Clin. Endocrinol. Metab. 105, e2192\u2013e2206 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1369_CR31","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.2337\/dc10-0814","volume":"33","author":"C Bizzarri","year":"2010","unstructured":"Bizzarri, C. et al. No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: The imdiab xiii trial. Diabetes Care 33, 1962\u20131963 (2010).","journal-title":"Diabetes Care"},{"key":"1369_CR32","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.3390\/nu11092185","volume":"11","author":"M Infante","year":"2019","unstructured":"Infante, M. et al. Influence of vitamin d on islet autoimmunity and beta-cell function in type 1 diabetes. Nutrients 11, 2185 (2019).","journal-title":"Nutrients"},{"key":"1369_CR33","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S2213-8587(21)00181-9","volume":"9","author":"BO Roep","year":"2021","unstructured":"Roep, B. O. et al. Defining a cure for type 1 diabetes: a call to action. Lancet Diabetes Endocrinol. 9, 553\u2013555 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1369_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2337\/dc19-0880","volume":"43","author":"M Battaglia","year":"2020","unstructured":"Battaglia, M. et al. Introducing the endotype concept to address the challenge of disease heterogeneity in type 1 diabetes. Diabetes Care 43, 5\u201312 (2020).","journal-title":"Diabetes Care"},{"key":"1369_CR35","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1210\/clinem\/dgaa205","volume":"105","author":"X Li","year":"2020","unstructured":"Li, X. et al. Decline pattern of beta-cell function in adult-onset latent autoimmune diabetes: An 8-year prospective study. J. Clin. Endocrinol. Metab. 105, 2231\u20132240 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1369_CR36","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2337\/db12-0207","volume":"62","author":"Z Zhou","year":"2013","unstructured":"Zhou, Z. et al. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in china (lada china study): a nationwide, multicenter, clinic-based cross-sectional study. Diabetes 62, 543\u2013550 (2013).","journal-title":"Diabetes"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01369-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01369-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01369-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:02:33Z","timestamp":1681948953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01369-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1369"],"URL":"https:\/\/doi.org\/10.1038\/s41392-023-01369-9","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"assertion":[{"value":"17 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ADVENT study was sponsored by grant 2013BAI09B12 and 2015BAI12B13 from National Science and Technology Infrastructure Program, grant 2021JC003 from the Natural Science Foundation of Hunan Province, and grant from AstraZeneca Investment (China) Co., Ltd. Z.Zho. reports grants from AstraZeneca and personal fees from Eli Lilly, Boehringer Ingelheim, Sanofi-Aventis, Merck, AstraZeneca, and Novo Nordisk. R.D.L. is on the advisory board of Diamyd. X.Y. reports grants from National Science and Technology Infrastructure Program and personal fees from Eli Lilly, Boehringer Ingelheim, AstraZeneca, Sanofi-Aventis. X.L. reports personal fees from Eli Lilly, Boehringer Ingelheim, Sanofi-Aventis, Merck, AstraZeneca, and Novo Nordisk. No other potential conflicts of interest relevant to this article were reported. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Z.Zho., X.Y. and L.X. received honoraria for lectures from AstraZeneca company, but these were provided outside the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"158"}}